X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15) 15
index medicus (14) 14
male (10) 10
female (9) 9
hematology (9) 9
aged (8) 8
middle aged (8) 8
adult (7) 7
leukemia (6) 6
oncology (6) 6
adults (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
survival rate (5) 5
abridged index medicus (4) 4
article (4) 4
cancer (4) 4
chemotherapy (4) 4
cytarabine - administration & dosage (4) 4
leukemia, myeloid, acute - drug therapy (4) 4
precursor cell lymphoblastic leukemia-lymphoma - drug therapy (4) 4
therapy (4) 4
treatment outcome (4) 4
young adult (4) 4
acute myeloid leukemia (3) 3
adolescent (3) 3
cytarabine (3) 3
daunorubicin - administration & dosage (3) 3
disease-free survival (3) 3
drug therapy (3) 3
hematology, oncology and palliative medicine (3) 3
inotuzumab ozogamicin - adverse effects (3) 3
patients (3) 3
remission (3) 3
remission induction (3) 3
research (3) 3
survival (3) 3
transplantation (3) 3
acute lymphatic leukemia (2) 2
acute myeloid-leukemia (2) 2
adjuvant therapy (2) 2
age factors (2) 2
aged, 80 and over (2) 2
antineoplastic agents, immunological - adverse effects (2) 2
children (2) 2
chronic myeloid leukemia (2) 2
clinical trials (2) 2
daunorubicin (2) 2
diarrhea (2) 2
dosage and administration (2) 2
drug resistance, neoplasm (2) 2
enzyme inhibitors - therapeutic use (2) 2
etoposide - administration & dosage (2) 2
follow-up studies (2) 2
group-b (2) 2
imatinib (2) 2
immunotherapy (2) 2
inotuzumab ozogamicin (2) 2
inotuzumab ozogamicin - administration & dosage (2) 2
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (2) 2
lymphatic leukemia (2) 2
minimal residual disease (2) 2
myeloid leukemia (2) 2
nausea (2) 2
neoplasms - drug therapy (2) 2
original (2) 2
palliative care (2) 2
patient outcomes (2) 2
pharmacology & pharmacy (2) 2
phase 3 (2) 2
precursor cell lymphoblastic leukemia-lymphoma - mortality (2) 2
prognosis (2) 2
protein (2) 2
protein kinase inhibitors - adverse effects (2) 2
protein kinase inhibitors - pharmacology (2) 2
recombinant interleukin-2 (2) 2
recurrence (2) 2
resistance (2) 2
risk factors (2) 2
time factors (2) 2
2013 accf/aha guideline (1) 1
506u78 (1) 1
9-beta-d-arabinofuranosylguanine (1) 1
[ sdv.can ] life sciences [q-bio]/cancer (1) 1
[sdv.can]life sciences [q-bio]/cancer (1) 1
abnormalities (1) 1
acute lymphoblastic leukemia (1) 1
acute lymphoblastic-leukemia (1) 1
acute lymphocytic leukemia (1) 1
acute lymphocytic-leukemia (1) 1
acute myelogenous leukemia (1) 1
adverse events (1) 1
agent (1) 1
alanine (1) 1
alanine transaminase (1) 1
alkaloids (1) 1
alternative medicine (1) 1
alternative therapies (1) 1
alzheimers-disease (1) 1
american-college (1) 1
aml (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Tefferi, Ayalew, MD and Kantarjian, Hagop, MD and Rajkumar, S. Vincent, MD and Baker, Lawrence H., DO and Abkowitz, Jan L., MD and Adamson, John W., MD and Advani, Ranjana Hira, MD and Allison, James, MD and Antman, Karen H., MD and Bast, Robert C., MD and Bennett, John M., MD and Benz, Edward J., MD and Berliner, Nancy, MD and Bertino, Joseph, MD and Bhatia, Ravi, MD and Bhatia, Smita, MD and Bhojwani, Deepa, MD and Blanke, Charles D., MD and Bloomfield, Clara D., MD and Bosserman, Linda, MD and Broxmeyer, Hal E., PhD and Byrd, John C., MD and Cabanillas, Fernando, MD and Canellos, George Peter, MD and Chabner, Bruce A., MD and Chanan-Khan, Asher, MD and Cheson, Bruce, MD and Clarkson, Bayard, MD and Cohn, Susan L., MD and Colon-Otero, Gerardo, MD and Cortes, Jorge, MD and Coutre, Steven, MD and Cristofanilli, Massimo, MD and Curran, Walter J., MD and Daley, George Q., MD, PhD and DeAngelo, Daniel J., MD, PhD and Deeg, H. Joachim, MD and Einhorn, Lawrence H., MD and Erba, Harry P., MD, PhD and Esteva, Francisco J., MD, PhD and Estey, Elihu, MD and Fidler, Isaiah J., DVM, PhD and Foran, James, MD and Forman, Stephen, MD and Freireich, Emil, MD and Fuchs, Charles, MD, MPH and George, James N., MD and Gertz, Morie A., MD and Giralt, Sergio, MD and Golomb, Harvey, MD and Greenberg, Peter, MD and Gutterman, Jordan, MD and Handin, Robert I., MD and Hellman, Samuel, MD and Hoff, Paulo Marcelo, MD and Hoffman, Ronald, MD and Hong, Waun Ki, MD and Horowitz, Mary, MD, MS and Hortobagyi, Gabriel N., MD and Hudis, Clifford, MD and Issa, Jean Pierre, MD and Johnson, Bruce Evan, MD and Kantoff, Philip W., MD and Kaushansky, Kenneth, MD and Khayat, David, MD, PhD and Khuri, Fadlo R., MD and Kipps, Thomas J., MD, PhD and Kripke, Margaret, PhD and Kyle, Robert A., MD and Larson, Richard A., MD and Lawrence, Theodore S., MD, PhD and Levine, Ross, MD and Link, Michael P., MD and Lippman, Scott M., MD and Lonial, Sagar, MD and Lyman, Gary H., MD, MPH and Markman, Maurie, MD and Mendelsohn, John, MD and Meropol, Neal J., MD and Messinger, Yoav, MD and Mulvey, Therese M., MD and O’Brien, Susan, MD and Perez-Soler, Roman, MD and Pollock, Raphael, MD, PhD and Prchal, Josef, MD and Press, Oliver, MD, PhD and Radich, Jerald, MD and Rai, Kanti, MD and Rosenberg, Saul A., MD and Rowe, Jacob M., MD and Rugo, Hope, MD and Runowicz, Carolyn D., MD and Sandmaier, Brenda M., MD and Saven, Alan, MD and Schafer, Andrew I., MD and Schiffer, Charles, MD and Sekeres, Mikkael A., MD, MS and Silver, Richard T., MD and Siu, Lillian L., MD and Steensma, David P., MD and ...
Mayo Clinic Proceedings, ISSN 0025-6196, 2015, Volume 90, Issue 8, pp. 996 - 1000
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 07/2019, Volume 125, Issue 14, pp. 2474 - 2487
Journal Article
Science Translational Medicine, ISSN 1946-6234, 03/2018, Volume 10, Issue 431, p. eaam8460
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2009, Volume 63, Issue 5, pp. 859 - 864
Journal Article
American Journal of Hematology, ISSN 0361-8609, 11/2018, Volume 93, Issue 11, pp. 1301 - 1310
Journal Article
CANCER, ISSN 0008-543X, 04/2014, Volume 120, Issue 7, pp. 1010 - 1017
BACKGROUNDRecombinant interleukin-2 (rIL-2) induces cellular cytotoxicity against leukemia blasts. Patients with acute myeloid leukemia (AML) in first complete... 
SURVIVAL | NATURAL-KILLER-CELLS | ACUTE MYELOGENOUS LEUKEMIA | ADULTS | adjuvant therapy | HIGH-DOSE CYTARABINE | CANCER | INTENSIFICATION THERAPY | TRANSPLANTATION | phase 3 | acute myeloid leukemia | ONCOLOGY | recombinant interleukin-2 | immunotherapy | IN-VIVO | GROUP-B
Journal Article
Journal of hematology & oncology, ISSN 1756-8722, 12/2018, Volume 11, Issue 1, pp. 143 - 12
Journal Article
Journal of Neuropathology & Experimental Neurology, ISSN 0022-3069, 10/2018, Volume 77, Issue 10, pp. 877 - 882
Abstract Chimeric antigen receptor (CAR) T cells are a new and powerful class of cancer immunotherapeutics that have shown potential for the treatment of... 
Cytokine release syndrome (CRS) | Chimeric antigen receptor T cells | Neurotoxicity | Cerebral edema | Chimeric antigen receptor (CAR) T cells | Blood-brain barrier (BBB) | PATHOLOGY | NEUROSCIENCES | CLINICAL NEUROLOGY | CHILDREN | REMISSIONS | LEUKEMIA | BRAIN | Edema | Lymphocytes
Journal Article